All In Biotech

Drug Trial Radar · NCT01012297

Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma

A Randomized Phase III Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF With Bevacizumab (NSC #704865) Versus Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF With Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus

Last checked: Nov 20, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 107 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

107

Actual

Start

Nov 2009

Primary completion

Sep 2015

Study completion Sep 2015

Sponsor

Sponsor type
NIH
Collaborators
NRG Oncology
First posted
Nov 13, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III trial is studying gemcitabine hydrochloride, docetaxel, and bevacizumab to see how well they work compared with gemcitabine hydrochloride, docetaxel, and a placebo in treating patients with advanced or recurrent uterine leiomyosarcoma. Drugs used in chemotherapy, such as gemcitabine hydrochloride and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether gemcitabine hydrochloride and docetaxel are more effective when given with or without bevacizumab in treating uterine leiomyosarcoma.

Conditions

  • Recurrent Uterine Corpus Sarcoma
  • Stage IIIA Uterine Sarcoma
  • Stage IIIB Uterine Sarcoma
  • Stage IIIC Uterine Sarcoma
  • Stage IVA Uterine Sarcoma
  • Stage IVB Uterine Sarcoma
  • Uterine Corpus Leiomyosarcoma

Interventions

  • BevacizumabBiological

    Given IV

  • DocetaxelDrug

    Given IV

  • FilgrastimBiological

    Given SC

  • Gemcitabine HydrochlorideDrug

    Given IV

  • PegfilgrastimBiological

    Given SC

  • PlaceboOther

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free SurvivalTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

Locations

201 sites in 1 country. Site status is shown where the registry gives one.

  • Saint Joseph's Hospital and Medical Center

    Phoenix, Arizona

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California

  • John Muir Medical Center-Concord Campus

    Concord, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California

  • Los Angeles County-USC Medical Center

    Los Angeles, California

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California

  • Palo Alto Medical Foundation-Gynecologic Oncology

    Mountain View, California

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California

  • University of California San Diego

    San Diego, California

  • UCSF Medical Center-Mount Zion

    San Francisco, California

  • Olive View-University of California Los Angeles Medical Center

    Sylmar, California

  • John Muir Medical Center-Walnut Creek

    Walnut Creek, California

  • The Medical Center of Aurora

    Aurora, Colorado

  • University of Colorado Cancer Center - Anschutz Cancer Pavilion

    Aurora, Colorado

  • Boulder Community Hospital

    Boulder, Colorado

  • Penrose-Saint Francis Healthcare

    Colorado Springs, Colorado

  • Porter Adventist Hospital

    Denver, Colorado

  • Exempla Saint Joseph Hospital

    Denver, Colorado

  • Presbyterian - Saint Lukes Medical Center - Health One

    Denver, Colorado

  • Rose Medical Center

    Denver, Colorado

  • Colorado Cancer Research Program CCOP

    Denver, Colorado

  • Rocky Mountain Gynecologic Oncology PC

    Englewood, Colorado

  • Swedish Medical Center

    Englewood, Colorado

  • Saint Mary's Hospital and Regional Medical Center

    Grand Junction, Colorado

  • North Colorado Medical Center

    Greeley, Colorado

  • Saint Anthony Hospital

    Lakewood, Colorado

  • Littleton Adventist Hospital

    Littleton, Colorado

  • Sky Ridge Medical Center

    Lone Tree, Colorado

  • Longmont United Hospital

    Longmont, Colorado

  • McKee Medical Center

    Loveland, Colorado

  • Parker Adventist Hospital

    Parker, Colorado

  • Saint Mary Corwin Medical Center

    Pueblo, Colorado

  • North Suburban Medical Center

    Thornton, Colorado

  • SCL Health Lutheran Medical Center

    Wheat Ridge, Colorado

  • Hartford Hospital

    Hartford, Connecticut

  • The Hospital of Central Connecticut

    New Britain, Connecticut

  • Beebe Medical Center

    Lewes, Delaware

  • Christiana Care Health System-Christiana Hospital

    Newark, Delaware

Showing 40 of 201 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.